JUPITER NEUROSCIENCES INC (JUNS) Fundamental Analysis & Valuation

NASDAQ:JUNS • US48208B2034

Current stock price

0.3988 USD
+0.02 (+4.04%)
At close:
0.3909 USD
-0.01 (-1.98%)
After Hours:

This JUNS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. JUNS Profitability Analysis

1.1 Basic Checks

  • In the past year JUNS has reported negative net income.
  • In the past year JUNS has reported a negative cash flow from operations.
  • In the past 5 years JUNS always reported negative net income.
  • In the past 5 years JUNS always reported negative operating cash flow.
JUNS Yearly Net Income VS EBIT VS OCF VS FCFJUNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M

1.2 Ratios

  • JUNS has a worse Return On Assets (-155.37%) than 86.53% of its industry peers.
Industry RankSector Rank
ROA -155.37%
ROE N/A
ROIC N/A
ROA(3y)-1137.96%
ROA(5y)-1228.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JUNS Yearly ROA, ROE, ROICJUNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

1.3 Margins

  • JUNS has a better Gross Margin (80.73%) than 85.49% of its industry peers.
  • JUNS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JUNS Yearly Profit, Operating, Gross MarginsJUNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. JUNS Health Analysis

2.1 Basic Checks

  • JUNS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for JUNS has been increased compared to 5 years ago.
  • Compared to 1 year ago, JUNS has a worse debt to assets ratio.
JUNS Yearly Shares OutstandingJUNS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
JUNS Yearly Total Debt VS Total AssetsJUNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M

2.2 Solvency

  • Based on the Altman-Z score of -13.38, we must say that JUNS is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -13.38, JUNS is doing worse than 78.76% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.38
ROIC/WACCN/A
WACCN/A
JUNS Yearly LT Debt VS Equity VS FCFJUNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 2M -2M 4M -4M -6M

2.3 Liquidity

  • JUNS has a Current Ratio of 0.65. This is a bad value and indicates that JUNS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • JUNS has a worse Current ratio (0.65) than 91.71% of its industry peers.
  • JUNS has a Quick Ratio of 0.65. This is a bad value and indicates that JUNS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Quick ratio value of 0.63, JUNS is not doing good in the industry: 89.12% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.65
Quick Ratio 0.63
JUNS Yearly Current Assets VS Current LiabilitesJUNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. JUNS Growth Analysis

3.1 Past

  • JUNS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -212.13%.
  • JUNS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -54.57% yearly.
EPS 1Y (TTM)-212.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-54.62%
Revenue growth 5Y-54.57%
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, JUNS will show a decrease in Earnings Per Share. The EPS will decrease by -1.58% on average per year.
  • JUNS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 890.48% yearly.
EPS Next Y123.81%
EPS Next 2Y-1.58%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16076.5%
Revenue Next 2Y890.48%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JUNS Yearly Revenue VS EstimatesJUNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2025 2026 2027 2M 4M 6M 8M 10M
JUNS Yearly EPS VS EstimatesJUNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 -0.1 -0.2

More info and screens

Find the best growth stocksShow best growing peers

4

4. JUNS Valuation Analysis

4.1 Price/Earnings Ratio

  • JUNS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 6.52 indicates a rather cheap valuation of JUNS.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of JUNS indicates a rather cheap valuation: JUNS is cheaper than 93.78% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of JUNS to the average of the S&P500 Index (23.54), we can say JUNS is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 6.52
JUNS Price Earnings VS Forward Price EarningsJUNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JUNS Per share dataJUNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.58%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. JUNS Dividend Analysis

5.1 Amount

  • JUNS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JUNS Fundamentals: All Metrics, Ratios and Statistics

JUPITER NEUROSCIENCES INC

NASDAQ:JUNS (4/10/2026, 8:00:02 PM)

After market: 0.3909 -0.01 (-1.98%)

0.3988

+0.02 (+4.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-01
Earnings (Next)N/A
Inst Owners4.44%
Inst Owner Change0%
Ins Owners43.61%
Ins Owner Change0%
Market Cap14.47M
Revenue(TTM)21.80K
Net Income(TTM)-8.64M
Analysts82.86
Price Target25.5 (6294.18%)
Short Float %0.5%
Short Ratio0.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.19%
Min EPS beat(2)6.16%
Max EPS beat(2)14.22%
EPS beat(4)3
Avg EPS beat(4)-10.26%
Min EPS beat(4)-63.4%
Max EPS beat(4)14.22%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 6.52
P/S 663.69
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)0.06
Fwd EY15.35%
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -155.37%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.73%
FCFM N/A
ROA(3y)-1137.96%
ROA(5y)-1228.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.65
Quick Ratio 0.63
Altman-Z -13.38
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-212.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-34%
EPS Next Y123.81%
EPS Next 2Y-1.58%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-54.62%
Revenue growth 5Y-54.57%
Sales Q2Q%N/A
Revenue Next Year16076.5%
Revenue Next 2Y890.48%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-188.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-38.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.42%
OCF growth 3YN/A
OCF growth 5YN/A

JUPITER NEUROSCIENCES INC / JUNS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of JUPITER NEUROSCIENCES INC (JUNS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to JUNS.


Can you provide the valuation status for JUPITER NEUROSCIENCES INC?

ChartMill assigns a valuation rating of 4 / 10 to JUPITER NEUROSCIENCES INC (JUNS). This can be considered as Fairly Valued.


Can you provide the profitability details for JUPITER NEUROSCIENCES INC?

JUPITER NEUROSCIENCES INC (JUNS) has a profitability rating of 1 / 10.


What is the financial health of JUPITER NEUROSCIENCES INC (JUNS) stock?

The financial health rating of JUPITER NEUROSCIENCES INC (JUNS) is 0 / 10.